NasdaqCM - Delayed Quote USD

Scienture Holdings, Inc. (SCNX)

3.2200 -0.2800 (-8.00%)

At close: October 30 at 4:00:01 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027

GlobeNewswire 9d ago

SCNX
-8.00%
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

GlobeNewswire 18d ago

SCNX
-8.00%
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

Benzinga 18d ago

SCNX
-8.00%
Scienture Holdings, Inc. Announces Reverse Stock Split

GlobeNewswire 1mo ago

SCNX
-8.00%
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

GlobeNewswire 4mo ago

SCNX
-8.00%
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

Benzinga 4mo ago

SCNX
-8.00%
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

GlobeNewswire 4mo ago

SCNX
-8.00%
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

GlobeNewswire 5mo ago

SCNX
-8.00%
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

GlobeNewswire 5mo ago

SCNX
-8.00%
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

GlobeNewswire 6mo ago

SCNX
-8.00%
Scienture Holdings: Q3 Earnings Snapshot

Associated Press Finance 11mo ago

SCNX
-8.00%
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

GlobeNewswire 29d ago

SCNX
-8.00%

Performance Overview

Return	SCNX	S&P 500 (^GSPC)
YTD	-74.75%	+10.73%
1-Year	-83.23%	+11.11%
3-Year	-96.51%	+81.91%

U.S. markets closed

Scienture Holdings, Inc. (SCNX)

SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

Scienture Holdings, Inc. Announces Reverse Stock Split

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Scienture Holdings: Q3 Earnings Snapshot

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals